KNE Kane Biotech Inc.

Kane Biotech Launches silkstemâ„¢ Anti-Itch Shampoo at the Global Pet Expo

Kane Biotech Launches silkstem™ Anti-Itch Shampoo at the Global Pet Expo

WINNIPEG, Manitoba, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced the launch of its silkstemTM anti-itch shampoo () at the Global Pet Expo taking place on February 26-28, 2020 at the Orange County Convention Center in Orlando, Florida. 

silkstemTM is a scientifically formulated anti-itch shampoo for dogs and cats that contains coactiv+TM, Kane’s patented anti-biofilm formulation, to soothe irritation, itching, redness and dryness associated with common skin conditions. silkstemTM is the first and only pet shampoo on the market in an aerosol can, making it significantly easier to apply than other pet shampoos.

“The launch of silkstemTM is an important milestone for Kane Biotech as it’s our second animal health product line and we believe it will generate the same amount of interest as our bluestem™ line of oral care products,” said Marc Edwards, CEO of Kane Biotech. “We believe pet parents will appreciate the skin health benefits that silkstemTM  provides, along with its quick spray foam application that makes it easier to give their pets a bath.”

Kane Biotech will be located in booth 4151 and will be accepting orders for its silkstemTM as well as its bluestemTM oral care line of products from U.S. retailers. Kane Biotech is also launching silkstemTM on on March 4th, 2020.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Corporation has a portfolio of biotechnologies, intellectual property (56 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNBTM, DispersinB®, Aledex®, bluestemTM, silkstemTM, coactiv+TM and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE".

For more information, please visit , or contact:

Marc Edwards 
Chief Executive Officer 
Kane Biotech Inc. 
+1 (514) 910-6991
  
Michel Stébenne 
VP Animal Health 
Kane Biotech Inc. 
+1 (204) 298-2200
  
Stephen Kilmer 
Investor Relations 
+1 (646) 274-3580

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.

 

EN
26/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kane Biotech Inc.

 PRESS RELEASE

Kane Biotech Announces Publication of revyve® Wound Gel Article in the...

Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal WINNIPEG, Manitoba, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE) (“Kane Biotech” or “Kane”) announces the publication of an article on its revyve® Antimicrobial wound gel in the International Wound Journal. The article “Wound Healing Property of a Novel Thermo-Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity” is first-authored by Dr. Jeyachchandran Visvalingam, Internal R&D Leader, and includes authors from the Miller School of Medicine, Dr. Philli...

 PRESS RELEASE

Kane Biotech Expands Commercial Activities in the United States

Kane Biotech Expands Commercial Activities in the United States WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has signed non-exclusive distribution/sales agreements for its revyve® Antimicrobial Wound Gel® product line with Patient Care Medical (Austin, TX) and Life Biologics (Lakewood, NJ). US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray These U.S. non-exclusive distribution and sales agreements expand our prese...

 PRESS RELEASE

Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial ...

Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser Company expands ISO 13485/MDSAP Certification to support growing wound care portfolio WINNIPEG, Manitoba, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE) (“Kane Biotech”. “Kane” or the “Company”) today announces two regulatory milestones that strengthen the Company’s wound care platform and reinforce its commitment to high quality, evidence-based medical device development. Kane has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its revyve® Antimicrobial S...

 PRESS RELEASE

Kane Biotech Restarts Commercial Activities and Strengthens North Amer...

Kane Biotech Restarts Commercial Activities and Strengthens North American Management Company enters 2026 with renewed business momentum and key commercial appointments in the U.S. and Canada WINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces the resumption of commercial activities in both the United States and Canada for its revyve® Antimicrobial Wound Gel product line, alongside the appointment of two seasoned industry leaders to drive business development across North America.                ...

 PRESS RELEASE

Kane Biotech Announces Closing of Private Placement Offering with an I...

Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces that today it has completed its previously announced non-brokered private placement offering (the “Offering”) of common shares of the Company (“Shares”). At the closing of the Offering, Kane issued 14,000,000 Shares at a price of $0.05 per Share for gross proceeds of $700,000 t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch